HARBIN, China, Aug. 14 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. (''China Sky One Medical'' or ''the Company'') (Amex: CSY), a leading fully integrated pharmaceutical company producing external use, over-the-counter drugs in the People's Republic of China ("PRC"), today announced that it successfully developed a nasal spray for the treatment and prevention of rheumatic disease.
Heilongjiang Tianlong Pharmaceutical, Inc. (''Tianlong''), a wholly-owned subsidiary of China Sky One Medical, Inc., recently completed research and development for the spray, which includes the active ingredients Naphazoline Hydrochloride Chlorpheniramine Maleate and Benzalkonium Bromide. Rheumatic diseases are shown in common sympathies and characterized by joint inflammation. There are currently only five other manufacturers of the spray in China and China Sky One has obtained the necessary approvals for production.
''We are very excited about the development of this spray, which serves a huge market in China,'' said Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical, Inc. ''We expect to launch the spray in the fourth quarter of 2008, and estimate that sales will add $500,000 to revenue in the fourth quarter.''
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding
company. The Company engages in the manufacturing, marketing and
distribution of pharmaceutical, medicinal and diagnostic products. Through
its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and
Technology Company (''TDR'') and Harbin First Bio- Engineering Company
Limited ("First"), the Company manufactures and distributes
over-the-counter pharmaceutical products, which make up
|SOURCE China Sky One Medical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved